Oncology Central

Intratumor and circulating clonal heterogeneity shape the basis of precision breast cancer therapy


The recent evidence of spatiotemporal genomes and tumor evolution has led to the development of breakthrough next-generation sequencing (NGS) technologies. Intratumor heterogeneity (ITH) and circulating clonal diversity represent two of the most possible explanations of primary and secondary resistance. In this editorial, we discuss how extensive biobanking for each individual patient with subsequent genome sequencing can open novel horizons for precision medicine in breast cancer.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.